Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid

Antiviral Research

Volumn 99, Issue 2, 2013, Pages 172-179

  Vázquez Calvo, Ángela ^a   Martín Acebes, Miguel A ^a   Sáiz, Juan Carlos ^b   Ngo, Nhi ^c   Sobrino, Francisco ^a   de la Torre, Juan Carlos ^c  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b INIA   (Spain)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antiviral; Budding; LCMV; Valproic acid

Indexed keywords

VALPROIC ACID; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; VIROGENESIS; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL; BUDDING; LCMV; VALPROIC ACID;

ANIMALS; ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DRUG DISCOVERY; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; RNA, VIRAL; VALPROIC ACID; VERO CELLS; VIRUS RELEASE; VIRUS REPLICATION;

ARENAVIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 84879218406     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.05.012     Document Type: Article

References (38)

1. Barton L.L., Mets M.B., Beauchamp C.L. Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am. J. Obstet. Gynecol. 2002, 187:1715-1716.
2. Battegay M. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24 well plates. ALTEX 1993, 10:6-14.
3. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287:2391-2405.
4. Bruni J., Wilder B.J. Valproic acid. Review of a new antiepileptic drug. Arch. Neurol. 1979, 36:393-398.
5. Buchmeier M.J., Peters C.J., de la Torre J.C. Arenaviridae: The Viruses and Their Replication. Fields Virology 2007, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA. fifth ed.
6. Buchmeier M.J., Lewicki H.A., Tomori O., Oldstone M.B. Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology 1981, 113:73-85.
7. Capul A.A., de la Torre J.C. A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology 2008, 382:107-114.
8. Cornu T.I., de la Torre J.C. RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J. Virol. 2001, 75:9415-9426.
9. Cramer J.A., Mattson R.H., Bennett D.M., Swick C.T. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther. Drug Monit. 1986, 8:411-415.
10. Emonet S.F., Garidou L., McGavern D.B., de la Torre J.C. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl. Acad. Sci. USA 2009, 106:3473-3478.
11. Geisbert T.W., Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 2004, 10:S110-S121.
12. Jahrling P.B., Peters C.J. Lymphocytic choriomeningitis virus. A neglected pathogen of man. Arch. Pathol. Lab. Med. 1992, 116:486-488.
13. Kanner A.M. The pharmacology of parenteral valproate. Epilepsy Curr. 2003, 3:109-111.
14. Kunz S. Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction. Virology 2009, 387:245-249.
15. Kunz S., Borrow P., Oldstone M.B. Receptor structure, binding, and cell entry of arenaviruses. Curr. Top. Microbiol. Immunol. 2002, 262:111-137.
16. Lee K.J., Novella I.S., Teng M.N., Oldstone M.B., de La Torre J.C. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 2000, 74:3470-3477.
17. Lee K.J., Pérez M., Pinschewer D.D., de la Torre J.C. Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J. Virol. 2002, 76:6393-6397.
18. Li S.Y., Chen C., Zhang H.Q., Guo H.Y., Wang H., Wang L., Zhang X., Hua S.N., Yu J., Xiao P.G., Li R.S., Tan X. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res. 2005, 67:18-23.
19. Martin V., Abia D., Domingo E., Grande-Perez A. An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis. J. Gen. Virol. 2010, 91:990-1003.
20. Mets M.B., Barton L.L., Khan A.S., Ksiazek T.G. Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. Am. J. Ophthalmol. 2000, 130:209-215.
21. Pérez M., Craven R.C., de la Torre J.C. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. USA 2003, 100:12978-12983.
22. Perez M., Greenwald D.L., de la Torre J.C. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J. Virol. 2004, 78:11443-11448.
23. Peters C.J. Human infection with arenaviruses in the Americas. Curr. Top. Microbiol. Immunol. 2002, 262:65-74.
24. Rodrigo W.W., de la Torre J.C., Martínez-Sobrido L. Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses. J. Virol. 2011, 85:1684-1695.
25. Shaltiel G., Shamir A., Shapiro J., Ding D., Dalton E., Bialer M., Harwood A.J., Belmaker R.H., Greenberg M.L., Agam G. Valproate decreases inositol biosynthesis. Biol. Psychiatry 2004, 56:868-874.
26. Snell N. Ribavirin therapy for lassa fever. Practitioner 1988, 232:432.
27. Strecker T., Eichler R., Meulen J., Weissenhorn W., Dieter Klenk H., Garten W., Lenz O. Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles. J. Virol. 2003, 77:10700-10705. (corrected).
28. Terbach N., Williams R.S. Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 2009, 37:1126-1132.
29. Tokuoka S.M., Saiardi A., Nurrish S.J. The mood stabilizer valproate inhibits both inositol- and diacylglycerol-signaling pathways in Caenorhabditis elegans. Mol. Biol. Cell 2008, 19:2241-2250.
30. Urata S., Ngo N., de la Torre J.C. The PI3K/Akt pathway contributes to arenavirus budding. J. Virol. 2012, 86:4578-4585.
31. Urata S., Noda T., Kawaoka Y., Yokosawa H., Yasuda J. Cellular factors required for Lassa virus budding. J. Virol. 2006, 80:4191-4195.
32. Urata S., Yasuda J., de la Torre J.C. The z protein of the new world arenavirus tacaribe virus has bona fide budding activity that does not depend on known late domain motifs. J. Virol. 2009, 83:12651-12655.
33. Vazquez-Calvo A., Saiz J.C., Sobrino F., Martin-Acebes M.A. Inhibition of enveloped virus infection of cultured cells by valproic acid. J. Virol. 2011, 85:1267-1274.
34. Venkataramani V., Rossner C., Iffland L., Schweyer S., Tamboli I.Y., Walter J., Wirths O., Bayer T.A. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J. Biol. Chem. 2010, 285:10678-10689.
35. Weber E.L., Buchmeier M.J. Fine mapping of a peptide sequence containing an antigenic site conserved among arenaviruses. Virology 1988, 164:30-38.
36. Wittenburg L.A., Bisson L., Rose B.J., Korch C., Thamm D.H. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol 2011, 67:83-92.
37. Wolf M.C., Freiberg A.N., Zhang T., Akyol-Ataman Z., Grock A., Hong P.W., Li J., Watson N.F., Fang A.Q., Aguilar H.C., Porotto M., Honko A.N., Damoiseaux R., Miller J.P., Woodson S.E., Chantasirivisal S., Fontanes V., Negrete O.A., Krogstad P., Dasgupta A., Moscona A., Hensley L.E., Whelan S.P., Faull K.F., Holbrook M.R., Jung M.E., Lee B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. USA 2010, 107:3157-3162.
38. Xu X., Muller-Taubenberger A., Adley K.E., Pawolleck N., Lee V.W., Wiedemann C., Sihra T.S., Maniak M., Jin T., Williams R.S. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot. Cell 2007, 6:899-906.